Copyright © 2001 by the European Society of Cardiology.
Editorials
Why patients with heart failure die
Institute for Cardiovascular Research, Leeds General Infirmary, Leeds, U.K.
References
- Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Med. 1985;27:335371
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145153
[Abstract/Free Full Text] - N Engl J Med. 1991;325:293302[Abstract]
- N Engl J Med. 1992;327:685691[Abstract]
- Lancet. 1999;353:913[CrossRef][Web of Science][Medline]
- Lancet. 1999;353:20012007[CrossRef][Web of Science][Medline]
- Cleland JGF, Thygesen K, Uretsky BF. Cardiovascular critical event pathways for the progression of heart failure: a report from the ATLAS study. Eur Heart J. 2001;22:16011612
[Abstract/Free Full Text] - Cleland JGF, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997;18:4151[Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||